1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Empire State Realty Trust and its operating partnership entered a First Amendment to their credit agreement with Wells Fargo as administrative agent, creating term loan and delayed draw term loan facilities of up to $490 million in initial principal, with a possible increase to $510 million. The term loan of $245 million was already fully borrowed before the closing date, and the delayed draw of $245 million may be drawn over the six months after July 17, 2026, with the facility funding working capital, capital expenditures, acquisitions, and development.
Facility totals up to $490 million: a $245 million term loan (fully borrowed before July 17, 2026) and a $245 million delayed draw term loan
Maximum aggregate principal may be increased to $510 million
Floating rates are SOFR plus 1.50% to 2.05%, or base rate plus 0.50% to 1.05%, depending on leverage ratio; delayed draw unused fee is 0.20%
Term loan matures January 15, 2029 (extendable to January 15, 2031); delayed draw matures January 12, 2032
Penguin Solutions issued $750.0 million of 0.00% convertible senior notes due August 1, 2031, including a $100.0 million option that the initial purchasers exercised in full. The company is using the estimated $735.1 million in net proceeds to repurchase $295.5 million of existing 2029 and 2030 convertible notes, pay $49.1 million for capped call transactions, and repay $100.0 million under a credit agreement. The new notes are convertible at an initial price of about $116.70 per share, and the capped calls are intended to reduce potential dilution.
$750.0 million principal, 0.00% interest rate, maturing August 1, 2031; initial conversion price of about $116.70 per share
Estimated net proceeds of $735.1 million, including about $136.7 million to repurchase $135.5 million of 2029 notes and about $161.4 million to repurchase $160.0 million of 2030 notes
Capped call cost of about $49.1 million with an initial cap price of $175.05 per share; $100.0 million used to repay the credit agreement
Effective August 1, 2026, the board of Kestrel Heat, LLC, the general partner of Star Group, L.P., approved raising President and CEO Jeffrey M. Woosnam's annual salary from $531,742 to $750,000. The board, acting as the compensation committee, approved the change in executive session without Mr. Woosnam present, and said it aligns his pay with market competitive levels and reflects his leadership and performance.
Annual base salary rises from $531,742 to $750,000, effective August 1, 2026
Increase approved by the board acting as compensation committee, in executive session without Mr. Woosnam
Stated rationale: market competitive pay and his leadership in executing the company's strategic objectives
Alico, Inc. entered into a third amended and restated employment agreement with CEO John Kiernan effective July 14, 2026, extending his term through September 30, 2030. The filing also grants him up to 160,000 performance-based restricted stock units tied to 60-day volume-weighted average price targets from $40 to $110 per share.
Employment term extended through September 30, 2030; base salary of $550,000 in year one, rising to $650,000 by year five
Enhanced severance of 200% of annual base salary, payable over 24 months, if terminated without Cause or for Good Reason after a Change in Control
Discretionary performance bonus of up to $250,000 per year, plus real estate incentive bonuses, at least 75% payable in cash
Up to 160,000 PSUs tied to 60-day VWAP targets of $40 to $110 per share, with time-based vesting through 2030
Advanced Biomed Inc. gave notice on July 14, 2026 to terminate its June 6, 2025 purchase agreement with Helena Global Investment Opportunities I Ltd., which allowed the company to sell up to $25,000,000 of common stock to the investor at its discretion. The filing states no shares were sold under the agreement apart from commitment fee shares, and the termination takes effect July 21, 2026, so the company will no longer have this equity financing option.
Purchase agreement dated June 6, 2025 allowed sales of up to $25,000,000 of common stock to Helena Global Investment Opportunities I Ltd.
Termination notice delivered July 14, 2026 under Section 11.02(b), which requires five trading days' notice.
No advances were outstanding and all amounts owed, including commitment fee shares, were paid, per the filing.
NanoViricides, Inc. entered into an at-the-market sales agreement with D. Boral Capital LLC, allowing it to sell common stock from time to time under an existing shelf registration. The filing does not state a dollar amount or number of shares, and sales are not required to occur; the company pays a 2.0% commission on gross proceeds from any sales, which would add shares outstanding and dilute existing holders.
Agreement dated July 17, 2026, with D. Boral Capital LLC as sales agent
Commission of 2.0% of aggregate gross proceeds from each sale
Shares sold under Form S-3 (File No. 333-296550), declared effective June 15, 2026
Sales may be made on the NYSE American or in privately negotiated transactions with company consent
Petco's Chief Human Resources Officer, Holly May, notified CEO Joel Anderson on July 13, 2026, that she will resign for personal reasons. She will stay in her role during a transition period whose end date is to be mutually agreed, and the company has started a comprehensive search for a successor.
Holly May, Chief Human Resources Officer, gave notice of resignation on July 13, 2026, citing personal reasons.
May is expected to remain in her current position to help transition her duties until a mutually agreed date.
Petco has begun a comprehensive search for her successor; no successor is named in the filing.
Hilton Grand Vacations entered into Amendment No. 10 to its credit agreement, under which the Borrower incurred an $850.0 million new term loan maturing July 17, 2033. Proceeds will repay in full about $849.0 million of an existing term loan due 2028, with the remainder for general corporate purposes. The filing does not include financial results, but it refinances existing debt and extends the maturity of that borrowing to 2033.
New $850.0 million term loan; about $849.0 million of the existing term loan due 2028 will be repaid in full.
Matures July 17, 2033, with quarterly repayments of 0.25% of original principal starting with the quarter ending December 31, 2026.
Interest at Term SOFR plus 2.00% or base rate plus 1.00%, with a 0% Term SOFR floor.
Guaranteed by Holdings and subsidiary guarantors and secured by a first-priority interest in substantially all of their assets.
On July 14, 2026, Adobe's Executive Compensation Committee approved a form of retention letter with Chief Legal Officer Louise Pentland. It sets severance benefits if she is terminated without Cause or resigns for Good Reason, and the protections are designed to end 12 months after a new Chief Executive Officer starts. The filing does not name the incoming CEO or give a start date, so shareholders can see the cost terms but not the timing.
Severance on qualifying termination: a lump-sum payment of 12 months' base salary plus 100% of target annual bonus, plus COBRA premiums for up to 12 months.
If terminated before July 15, 2027, 50% of certain restricted stock unit awards (Retention RSUs) vest early.
If terminated before January 31, 2027, other time-based equity awards vest for the portion that would have vested through January 31, 2027.
The protections sunset 12 months after the new CEO commences employment; severance is conditioned on a release of claims.
Hims & Hers Health said Chief Accounting Officer and Principal Accounting Officer Irene Becklund will resign effective October 9, 2026, and she has said the decision is not tied to any disagreement over accounting or financial reporting. The company will retain her in an advisory role from October 10, 2026 through July 10, 2027, which gives it continuity during the transition of its accounting leadership.
Irene Becklund informed the company of her resignation on July 13, 2026, effective October 9, 2026.
Becklund has been Chief Accounting Officer since April 2025 and Principal Accounting Officer since November 2021.
She has stated the resignation is not the result of any dispute over accounting principles, practices, or financial statements.
An advisory agreement effective October 10, 2026 keeps her supporting the company until July 10, 2027.
Spire Global appointed Eric Mellinger, formerly a Vice President at Mantech International, as Chief Commercial Officer, effective August 3, 2026. He will lead the company's global commercial organization, including go-to-market strategy, business development, sales, and customer growth, and his employment agreement sets a $385,000 base salary and severance terms.
Annual base salary of $385,000 and target annual cash bonus of 80% of base salary
Grant of 150,000 restricted stock units under the 2021 Equity Incentive Plan, to be granted August 3, 2026
Without a change in control, a qualifying termination pays 100% of base salary and 100% of target bonus, plus 12 months of health coverage
Within the 18-month change-in-control period, severance rises to 150% of base salary and target bonus, and equity awards fully vest
International Paper's board appointed Katherine Collins and Lori J. Ryerkerk as independent directors, effective October 1, 2026. Directors Kathryn D. Sullivan and Ahmet C. Dorduncu will retire effective December 31, 2026, and the board will have 13 members, 12 of them independent. The filing describes the changes as governance updates and does not discuss financial results.
Katherine Collins and Lori J. Ryerkerk join the board effective October 1, 2026, with terms ending at the May 2027 shareowner meeting.
After the appointments, the board will have 13 members, 12 of whom are independent.
Dr. Kathryn D. Sullivan and Ahmet C. Dorduncu retire effective December 31, 2026, with no disagreement with the company cited.
Governance guidelines amended in March 2026 eliminate the mandatory retirement age of 75 and adopt a 12-year director term limit.
Lindsay Corporation's Chief Financial Officer, Sam Hinrichsen, plans to resign effective August 31, 2026, citing personal reasons and stating there were no disagreements with the company. The company says the departure is unrelated to its operations, policies, or accounting practices, and it has started a search for a new CFO with an executive recruiting firm.
Sam Hinrichsen resigns as Senior Vice President and Chief Financial Officer effective August 31, 2026
He will provide transition services from the effective date through December 31, 2026, under a written agreement filed as Exhibit 10.1
Transition payments include $100,000 for services and $110,000 tied to outstanding equity awards, plus his 2026 annual bonus under the Management Incentive Plan
The company is paying his COBRA premiums for four months and waived repayment of his cash signing bonus
Grayscale Investments Sponsors, LLC, sponsor of the Grayscale Sui Staking ETF, intends to sign Amendment No. 2 to the trust agreement on or around August 7, 2026. The amendment would require the trust to convert staking consideration to cash at least quarterly and distribute the net proceeds to shareholders, so shareholders could receive regular cash distributions for the first time under this framework. The filing says distribution amounts will depend on staking consideration actually received and cannot be predicted with certainty.
Proposed Amendment No. 2 to the trust agreement is expected on or around August 7, 2026, with trustee CSC Delaware Trust Company.
Trust would sell staking consideration to cash no less often than quarterly and distribute net proceeds, after trust expenses not assumed by the sponsor.
The sponsor gave shareholders 20 days' prior notice and states the amendment is not materially adverse to shareholders.
Tvardi Therapeutics filed a prospectus supplement on July 17, 2026, raising its at-the-market share sale capacity under its JonesTrading sales agreement by up to $9,689,765. The filing says the company is subject to the SEC's baby shelf rule, which caps sales based on non-affiliate market value, and that no further shares will be sold under the prior prospectus after the supplement date. For shareholders, the expansion signals potential dilution from additional share issuance.
On July 17, 2026, the company filed a prospectus supplement allowing issuance of up to $9,689,765 in shares, in addition to amounts previously sold.
Baby shelf limits apply: non-affiliate market value is $62,208,945, based on 12,441,789 shares at $5.00 on July 8, 2026.
In the prior twelve months, the company sold 3,110,769 shares for about $11.0 million in gross proceeds under the sales agreement.
The Sales Agreement with JonesTrading Institutional Services LLC was entered into on May 1, 2026; Cooley LLP's legal opinion is filed as Exhibit 5.1.
The Sponsor, Grayscale Investments Sponsors, LLC, intends to enter into a Third Amended and Restated Declaration of Trust and Trust Agreement on or around August 7, 2026, to start regular cash distributions of net staking reward proceeds to shareholders. The Sponsor says the change is not materially adverse to shareholders and conforms the trust to IRS Revenue Procedure 2025-31, but it gave 20 days' prior notice, and distribution amounts will depend on staking rewards actually received.
Trust would reduce staking consideration to cash no less often than quarterly and distribute net proceeds to shareholders.
Distribution amounts depend on staking consideration actually received and cannot be predicted with certainty.
Sponsor gave shareholders 20 days' prior notice; execution is anticipated on or around August 7, 2026.
Filing includes updated tax consequences and supplemental risk factors as Exhibits 99.1 and 99.2; shareholders are advised to consult tax advisers.
enGene Therapeutics furnished an updated corporate presentation on July 17, 2026, as Exhibit 99.1 to a Form 8-K under Regulation FD. The deck restates the company's pivotal-cohort interim results for detalimogene, its plans for a BLA filing, and cash of $285 million, with no new financial results or guidance stated in the filing.
Pivotal Cohort 1 (N=125, BCG-unresponsive high-risk NMIBC with CIS) shows an any-time complete response rate of 54% (95% CI: 44.9%, 63.0%) in data as of April 21, 2026
Pivotal cohort 12-month data and BLA filing are expected in 2H 2026, with potential approval and platform designation in 2027
The company cites $285 million in cash expected to fund operations through BLA filing and potential approval
The sponsor, Grayscale Investments Sponsors, LLC, intends to enter into a Fourth Amended and Restated Declaration of Trust on or around August 7, 2026, with 20 days' prior notice to shareholders. The amendment would require the trust to convert staking consideration to cash at least quarterly and distribute the net proceeds to shareholders, with amounts depending on staking rewards actually received. The filing states the sponsor considers the change not materially adverse to shareholders and tied to IRS Revenue Procedure 2025-31.
Proposed amendment intended for execution on or around August 7, 2026
Trust would reduce staking consideration to cash no less often than quarterly and distribute net proceeds to shareholders
Distribution amounts depend on staking consideration received and cannot be predicted with certainty
Shareholders advised to consult tax advisors; supplemental tax and risk disclosures filed as Exhibits 99.1 and 99.2
Csquare sold 50,000,000 shares of common stock at $21.00 per share in its initial public offering, with the sale closing on July 17, 2026 and providing net proceeds of $1,010.0 million. The company also entered agreements with Brookfield that give Brookfield board nomination rights and registration rights for its shares, and it amended its charter and bylaws in connection with the offering.
50,000,000 shares sold at $21.00 per share; underwriters have a 30-day option to buy up to 7,500,000 additional shares
Net proceeds to the company of $1,010.0 million after underwriter discounts and commissions; sale closed July 17, 2026
Stockholders Agreement with Brookfield lets it nominate directors while it owns at least 5% of outstanding common stock
Amended and restated certificate of incorporation and bylaws adopted July 15, 2026
The sponsor, Grayscale Investments Sponsors, LLC, intends to enter a Third Amended and Restated Declaration of Trust and Trust Agreement on or around August 7, 2026. The amendment would require the trust to convert staking consideration to cash at least quarterly and distribute the net proceeds to shareholders, though the amount of each distribution depends on staking rewards actually received and cannot be predicted with certainty. The sponsor says the change is intended to conform to IRS Revenue Procedure 2025-31, and it is giving shareholders 20 days' prior notice.
Proposed amendment is expected to take effect on or around August 7, 2026.
Trust would convert staking consideration to cash no less often than quarterly and distribute net cash proceeds to shareholders.
Sponsor gave 20 days' prior notice to shareholders; the filing says distribution amounts cannot be predicted with certainty.
Trust intends to file a Rule 424(b)(3) prospectus supplement upon execution, and filed tax and risk factor supplements as Exhibits 99.1 and 99.2.
Director Richard Lowenthal resigned from the ARS Pharmaceuticals board effective immediately on July 15, 2026, and Chief Medical Officer Sarina Tanimoto, M.D., ceased employment the same day in a termination without cause. The company agreed to one-time payments of $217,350 to Lowenthal and $111,780 to Tanimoto, each a prorated share of their 2026 target bonus, on top of severance described in the 2026 proxy statement. The filing gives no financial results or guidance, but it reports senior leadership departures and added costs.
Richard Lowenthal resigned from the Board effective immediately on July 15, 2026; his resignation was a condition for severance rights.
Sarina Tanimoto, M.D., Chief Medical Officer, ceased employment on July 15, 2026, under a termination without cause.
One-time payments: $217,350 to Lowenthal and $111,780 to Tanimoto, each a prorated 2026 target bonus.
Payments and severance are conditioned on the effectiveness of each executive's release of claims.
The Sponsor, Grayscale Investments Sponsors, LLC, intends to sign Amendment No. 2 to the Trust Agreement with trustee CSC Delaware Trust Company on or around August 7, 2026. The amendment would require the Trust to convert staking consideration to cash at least quarterly and distribute the net cash proceeds to Shareholders, and the amount of each distribution will depend on the staking consideration actually received and cannot be predicted with certainty.
The Sponsor intends to enter into Amendment No. 2 on or around August 7, 2026, with CSC Delaware Trust Company as trustee.
The amendment would require the Trust to reduce staking consideration to cash no less often than quarterly and distribute net proceeds to Shareholders.
Net proceeds are after Trust expenses not assumed by the Sponsor, which may include a portion of staking consideration paid to the Sponsor for facilitating staking.
The Sponsor gave Shareholders 20 days' prior notice, and the filing is dated July 17, 2026.
Gogo said Hayden Olson moved from executive vice president and general manager of SD Government to executive vice president of corporate development, effective July 15, 2026, as part of an internal reorganization of Satcom Direct Government, LLC. Under the filing, he is no longer an executive officer or officer under SEC rules, and the company says the reorganization should improve operating efficiency and support its previously disclosed synergy targets.
Effective date of the role change: July 15, 2026
New role covers strategic initiatives and military/government partnership and new revenue opportunities; he reports to CEO Christopher Moore
Olson is no longer designated an executive officer or officer under SEC rules
Filing is dated July 17, 2026 and signed by Crystal L. Gordon, General Counsel
Archimedes Tech SPAC Partners III Co. appointed Stephen N. Cannon as a Class II director effective immediately, after the board's July 13, 2026 action. He was also named to the audit, compensation, and nominating and corporate governance committees, and the board deemed him independent. The filing describes a board addition rather than a change in the company's financial results or business plans.
Board appointed Stephen N. Cannon as Class II director on July 13, 2026, effective immediately
Cannon named to audit, compensation, and nominating and corporate governance committees
Cannon is also a director of Archimedes Tech SPAC Partners II Co., which has a definitive merger agreement with Forge Nano Inc.
Company entered into a joinder to letter agreement, registration rights agreement and indemnification agreement with Cannon
Bassett Furniture Industries announced on July 16, 2026 that its Board declared a regular quarterly dividend of $0.20 per share. Shareholders of record at the close of business on August 14, 2026 will receive the payment on August 28, 2026. The filing covers only the dividend declaration and does not include financial results.
Regular quarterly dividend of $0.20 per share of common stock declared
Record date is the close of business on August 14, 2026
On July 13, 2026, Dream Finders Homes expanded its board from five to seven members and appointed Richard Beckwitt, former Co-Chief Executive Officer and Co-President of Lennar Corporation, as a director and Co-Chairman alongside CEO Patrick Zalupski. The board also appointed Steven Fischer, former President and CEO of TIAA Bank, as a director and member of the Audit Committee. The changes alter the company's board leadership structure and add a director the board has designated as an audit committee financial expert.
Board expanded from five to seven members; Beckwitt and Fischer appointed effective immediately on July 13, 2026
Beckwitt named Co-Chairman with CEO Patrick Zalupski and will receive 400,000 restricted stock units, subject to stockholder approval of an amendment to the 2021 Equity Incentive Plan
Fischer joins the Audit Committee, replacing Megha Parekh, and the board determined he is an audit committee financial expert
Press releases announcing the appointments are dated July 14, 2026 (Beckwitt) and July 17, 2026 (Fischer), furnished as Exhibits 99.1 and 99.2
Rayonier's board approved making Ryan Daniels Senior Vice President, Wood Products on a permanent basis, after he had served as interim head since March 20, 2026. His base salary rises to $450,000 and he becomes eligible for a 2026 cash bonus of 65% of earned base salary and salary stipend. The filing discloses no financial results, so the change is a leadership appointment rather than a change in reported performance.
Board approved the appointment on July 16, 2026; press release issued July 17, 2026.
Daniels previously served as interim SVP, Wood Products from March 20, 2026, and SVP, Operations from January 2026.
New base salary of $450,000, a cash bonus eligibility of 65% for 2026, and Tier II participation in the Executive Severance Pay Plan.
Daniels joined Rayonier through its merger with PotlatchDeltic, which closed in January 2026.
Medifast, Inc. announced on July 17, 2026 that its wholly owned subsidiary OPTAVIA is being rebranded as Trilivy, described as a comprehensive metabolic health system. The company also introduced newly formulated meal replacements, with the planned debut of these Fuelings in August. The filing, which furnishes a press release, includes no revenue, earnings, or guidance figures, so its direct financial effect on shareholders is not quantified.
Rebranding of OPTAVIA to Trilivy announced July 17, 2026, via a press release furnished as Exhibit 99.1
Trilivy Reset Fueling line, enhanced with MetaVantage Technology, accompanies the brand launch
Newly formulated meal replacements, called Fuelings, are planned to debut in August
The filing contains no financial results, guidance, or dollar figures
Columbia Financial, Inc. said it completed its firm commitment underwritten offering in its second-step conversion, selling 167,236,353 shares at $10.00 per share for total offering proceeds of $1.67 billion. The company also set the final merger consideration for its acquisition of Northfield Bancorp at an aggregate $580 million, with both transactions scheduled to close on July 20, 2026.
167,236,353 shares sold at $10.00 each, for total offering proceeds of $1.67 billion
Existing Holding Company minority shares will be exchanged for 2.2000 shares of Company common stock
Northfield stockholders receive $14.25 in cash or 1.425 shares per share, for aggregate merger consideration of $580 million
Closing scheduled for July 20, 2026; shares expected to trade on Nasdaq as CLBK starting July 21, 2026
Polaryx Therapeutics' board set its 2026 Annual Meeting of Stockholders to be held virtually on September 10, 2026, with a July 27, 2026 record date. The filing also sets a July 27, 2026 deadline for stockholder proposals and director nominations to be considered for the proxy materials, because the company held no annual meeting in 2025.
Annual Meeting to be held virtually on September 10, 2026
Stockholders of record at close of business on July 27, 2026 may vote
Deadline for stockholder proposals and director nominations for proxy inclusion is close of business on July 27, 2026
Company may change the record date, meeting date and location before the meeting
On July 15, 2026, Uniti Group subsidiary Kinetic ABS Issuer LLC completed a private offering of $1,140,710,000 in secured fiber network revenue term notes, the second issuance in its fiber-to-the-home securitization program. The company says it intends to use the net proceeds for general corporate purposes, which may include success-based capital expenditures and/or repaying debt.
Class A-2 notes $805,210,000 at 5.834%, Class B $134,200,000 at 6.224%, Class C $201,300,000 at 7.536%
Notes issued at 100% of principal, with an anticipated repayment date in June 2033 and a legal final maturity in June 2058
Interest is payable monthly on the 25th, starting August 25, 2026
About $91,081,390 is held in a prefunding account for Oklahoma assets pending regulatory approvals; if those sales do not close by July 30, 2027, the funds prepay the notes
IPG Photonics signed a put option agreement with Lumibird S.A. for the proposed acquisition of 100% of Lumibird Medical, a wholly owned subsidiary of the seller, for €300 million on a cash-free, debt-free basis, plus up to €50 million in contingent earnout tied to 2026 and 2027 performance. The company expects to fund the deal with cash on hand, and closing is expected in the fourth quarter of 2026, subject to a French works council consultation, French foreign direct investment authorization and other customary conditions. Shareholders should note the filing states the deal may not close on the anticipated timeline or at all.
Purchase price of €300 million on a cash-free, debt-free basis, payable in cash at closing, plus up to €50 million contingent earnout based on 2026 and 2027 metrics
Funding from cash on hand; closing expected in the fourth quarter of 2026
Put option becomes binding on IPG only after the seller delivers an exercise notice; if the seller does not exercise by the expiry date, it pays IPG €3.5 million
Lumibird Medical reported fiscal 2025 revenue of €112.2 million and IFRS EBITDA of €24.1 million, per the company's press release
Tribeca Strategic Acquisition Corp. said that starting July 20, 2026, holders of its IPO units may separate the units into Class A ordinary shares and share rights for separate trading on Nasdaq. Units not separated will keep trading as BIDWU, and the company's filing does not describe any change to its business or financial results.
Separate trading of Class A ordinary shares (BID) and share rights (BIDWR) begins July 20, 2026
Unseparated units continue to trade on Nasdaq under BIDWU
Each right entitles the holder to one-tenth of one Class A ordinary share upon completion of an initial business combination
Unit holders must have their brokers contact transfer agent Efficiency, INC. to separate units
Targa Resources Corp. appointed Thomas Mathiasmeier, a former ConocoPhillips executive, as a Class II director on July 16, 2026, with a term expiring at the 2027 annual meeting, and also named him to the Audit Committee. The filing describes him as a non-employee director who will receive standard director compensation and a pro-rated restricted stock award of 477 shares, and says the company entered into an indemnification agreement with him.
Appointed to the Board on July 16, 2026; Class II director with term expiring at the 2027 annual meeting
Also appointed to the Board's Audit Committee
Expected pro-rated restricted stock award of 477 shares under the 2010 Stock Incentive Plan
Previously served as President, Global Gas, Power & Emerging Markets at ConocoPhillips before retiring in June 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.